Urticaire solaire traitée par l’association immunoglobulines polyvalentes et PUVAthérapie

Darras, S.; Ségard, M.; Mortier, Laurent; Bonnevalle, A.; Thomas, Pierre

doi:10.1016/s0151-9638(04)93546-6

Cited by 28 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Studies performed on patients with chronic urticaria 5 or delayed pressure urticaria 14 showed 20% to 50% of complete response. Sporadic cases of refractory SU successfully treated with IVIG have been previously reported, [6][7][8]15 including 3 of our patients. [6][7][8] Our report shows that of 7 patients affected with severe SU who have been treated with IVIG in France, 5 experienced a considerable improvement after 1 to 3 courses (71% complete remission rate) and remission has been maintained for more than 1 year in 60% of the responsive patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Solar urticaria treated with intravenous immunoglobulins

Adamski

Bédane

Bonnevalle

et al. 2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Three of these cases (patients 1-3) have been previously reported. [6][7][8] There were 5 female and 2 male patients with a mean age of 40 years (range 32-55 years). The mean SU duration before IVIG treatment was 5 years (range 2-10 years).…”

Section: Patient Characteristicsmentioning

confidence: 99%

Solar urticaria treated with intravenous immunoglobulins

Adamski

Bédane

Bonnevalle

et al. 2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…IVIg is a polyvalent antibody product, derived from the pooled plasma of healthy donors, which is being increasingly used to treat dermatological diseases, including idiopathic chronic urticaria or delayed pressure urticaria (3). It is a well‐tolerated drug with minor side effects like infusion reactions.…”

Section: Discussionmentioning

confidence: 99%

“…There have only been a few reports in the literature of SU successfully treated with IVIg (1–5). Patients were aged from 27 to 55 years and their SU disease duration varied from 1 month to 5 years (1–5). The administration schedule differed from one patient to another: 2–2.5 g/kg, infused over 3–5 days and a wide range number of necessary courses (from 1 to 6), with variable time lags (from 1 to 3 months between the courses).…”

Section: Discussionmentioning

confidence: 99%

Solar urticaria unresponsive to intravenous immunoglobulins

Llamas‐Velasco

Argila

Eguren

et al. 2011

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

The treatment of solar urticaria (SU) can be difficult. Only a few cases of SU have been treated with intravenous immunoglobulins (IVIg) (as monotherapy or combined with phototherapy), with reported fast and durable increase of solar exposure tolerance. A 61-year-old female with severe UVB- and UVA-induced SU and a 62-year-old female with severe UVA and visible light-induced SU were both treated with a single course of IVIg (total dose of 2 g/kg), infused over 3 days. Phototest, performed 3 months after the treatment, showed only a slight minimal urticating dose improvement, and both patients reported just a moderate and 'transient' subjective improvement. Our patient's poorer response, compared with previous reports, may be due to differences in IVIg's treatment schedules, which are reviewed.

show abstract

“…Open studies performed on several patients affected with idiopathic chronic urticaria [3] or with delayed pressure urticaria showed 20–50% with complete response and 30% with partial remission. Two cases of refractory idiopathic SU successfully treated with IVIG have been previously reported (table 2) [4, 5]. In one case, IVIG were given alongside PUVA therapy.…”

Section: Discussionmentioning

confidence: 99%

Solar Urticaria Successfully Treated with Intravenous Immunoglobulins

et al. 2009

View full text Add to dashboard Cite

Background: Idiopathic solar urticaria (SU) is a rare type of physical urticaria, occurring immediately after exposure to visible or ultraviolet (UV) light. Treatment is based on sun avoidance and on high doses of antihistamines, but is sometimes inefficient. Methods: We report on a 41-year-old patient with severe SU who was successfully treated with a single course of 2 g/kg of intravenous immunoglobulins (IVIG). Results: A dramatic improvement in UVA and UVB tolerance was rapidly observed, with an increase of up to 10 times the UVA minimal urticarial dose on day 3. The treatment with terfenadine was continued. Healing of photosensitivity was persistent since 100 days after the single course of IVIG, no urticarian reaction was provoked with polychromatic irradiation rising above 8.3 J/cm² or after UVA doses rising above 15 J/cm². Conclusion: Use of IVIG in severe SU can be discussed when high-dose antihistamines are inefficient and quality of life is affected.

show abstract

Urticaire solaire traitée par l’association immunoglobulines polyvalentes et PUVAthérapie

Cited by 28 publications

References 13 publications

Solar urticaria treated with intravenous immunoglobulins

Solar urticaria treated with intravenous immunoglobulins

Solar urticaria unresponsive to intravenous immunoglobulins

Solar Urticaria Successfully Treated with Intravenous Immunoglobulins

Contact Info

Product

Resources

About